An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1060 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This observational study will evaluate the clinical benefit of NeoRecormon (epoetin beta) in daily routine practice in cancer patients with anemia. Data will be collected from patients who are receiving chemotherapy for a solid tumor or hematological malignancy. Patients will be followed for 28 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy

NCT01716559

Anemia

COMPLETED

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies

NCT02564094

Anemia

COMPLETED PHASE4

A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors

NCT02554942

Anemia

COMPLETED PHASE4

A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

NCT02761642

Anemia

COMPLETED PHASE2

Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors

NCT00559195

Anemia Fatigue Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia, Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

epoetin beta [NeoRecormon]

Intervention Type DRUG

As prescribed by physician

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

epoetin beta [NeoRecormon]

As prescribed by physician

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients, \>/=18 years of age
* Patients receiving myelosuppressive chemotherapy for a solid tumor, a hematological malignancy or an autograft for hematological malignancy
* Patients for whom treatment with epoetin beta is started at the inclusion visit
* Life expectancy \>/=6 months according to the physician
* Patients accepting and able to complete a French written questionnaire about his/her professional and social activities at each visit

Exclusion Criteria

* Patients who received erythropoiesis-stimulating agents treatment, or red blood cell transfusion within 4 weeks before enrollment
* Participation in a clinical trial in onco-hematology
* Patients with myelodysplasia
* Patients with more than one active malignancy at the time of enrollment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No